Reprogenesis Vascugel Restenosis Trial To Start This Year After Curis Merger
This article was originally published in The Gray Sheet
Executive Summary
Initial clinical trials of Reprogenesis' Vascugel for prevention of restenosis following coronary bypass surgery are anticipated to begin by year-end in 20-30 patients pending submission and approval of an investigational new drug application from FDA's biologics center.
You may also be interested in...
Curis, Inc.
Formation of the $600 mil.-cap biotechnology company focusing on regenerative medicine via the three-way merger of Creative Biomolecules, Ontogeny and Reprogenesis is complete July 31 following shareholder approvals. The deal was first announced in February (1"The Gray Sheet" June 12, p. 17). Nasdaq trading of Curis stock commenced on Aug. 1
Curis, Inc.
Formation of the $600 mil.-cap biotechnology company focusing on regenerative medicine via the three-way merger of Creative Biomolecules, Ontogeny and Reprogenesis is complete July 31 following shareholder approvals. The deal was first announced in February (1"The Gray Sheet" June 12, p. 17). Nasdaq trading of Curis stock commenced on Aug. 1
Creative BioMolecules/Stryker
Creative BioMolecules completes the sale of OP-1 morphogenic protein assets and manufacturing rights to Stryker. The deal, a definitive agreement for which was announced Oct. 16 ("The Gray Sheet" Oct. 19, p. 11), "significantly enhances" CBM's near term cash flow with the receipt of approximately $20 mil. and "the elimination of commercial manufacturing-related expenses and capital investments," the company says